Regular Coffee, Decaf and Tea All Associated with Reduced Risk for Diabetes: Individuals who drink more coffee (regular or decaffeinated) or tea appear to have a lower risk of developing Type 2 diabetes, according to an analysis of previous studies reported in the Archives of Internal Medicine, 14-Dec-2009. See this week’s …

Reducing TV Time Helps Adults Burn More Calories: Adults who used an electronic lock-out system to reduce their television time by half did not change their calorie intake but did expend more energy over a three-week period, according to a report in the Archives of Internal Medicine, 14-Dec-2009.  

Metabolic Syndrome Independently Ups Risk of Diabetes: The diagnosis of metabolic syndrome is useful and valuable for predicting Type 2 diabetes even in relatively lean patients. Even when the cutoff point of waist circumference for U.S. individuals was used in the metabolic syndrome criteria, the hazard ratio of metabolic syndrome …

Negative Pressure Wound Devices Draw FDA Notice, Advice: The FDA has notified health professionals, and advised patients, about rare but serious complications — including deaths — from the use of negative pressure wound therapy (NPWT). Negative pressure wound therapy devices can help in the healing and closure of wounds. They create …

Among people with diabetes, those who develop foot ulcers seem to die earlier than those without the complication, a new study finds.

Eli Lilly and Company, and Amylin announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with Type 2 diabetes.  

Elevated 1-hour plasma glucose (1hPG) levels in persons without overt diabetes (DM) may be a marker for cardiovascular risk, according to the results of a study.  

The drug rituximab already used to treat autoimmune disorders may also slow the destruction of insulin-producing cells in patients with insulin-dependent (Type 1) diabetes.

Novo Nordiskstarted the first human tests on an experimental insulin pill, NN1952, joining companies seeking to develop an alternative to daily injections for diabetes patients who need the hormone to control their disease.  

Proton pump inhibitor therapy is associated with improved hemoglobin A1c levels in non-insulin-dependent Type 2 diabetes patients, based on results from two retrospective studies.